Euromedica Executive Search successfully appoint Prof. Michael Heneka as the Director of the Luxembourg Centre for Systems Biomedicine

London, United Kingdom, 14th June 2021: Euromedica Executive Search are pleased to announce their successful partnership with the University of Luxembourg and the Luxembourg Centre for Systems Biomedicine (LCSB) to secure Prof. Michael Heneka, effective as of the 1st January 2022.

Prof. Heneka will succeed Prof. Rudi Balling, the founding director of the multi-disciplinary university centre which has grown over a period of 11 years to be one of the leading institutes in Parkinson’s Disease fundamental research.

Also now appointed to the University of Luxembourg as Professor of Neurological Medicine and Neurosciences by the Board of Governors, Prof. Heneka brings a wealth of experience in medicine, research and education to the University and the LCSB.
Prof. Michael Heneka is currently Director of the Department of Neurodegenerative Disease and Professor of Clinical Neurology at the University of Bonn (Germany). He is also adjunct professor at the Department of Infectious Diseases and Immunology at the University of Massachusetts Medical School, USA, as well as being the recipient of the Hans und Ilse Breuer Alzheimer Research Award (2013) and of the Christa-Lorenz Award for ALS Research (2011).

For further information regarding the details of Prof. Heneka’s appointment, please refer to
https://wwwen.uni.lu/university/news/slideshow/prof_michael_heneka_is_appointed_director_of_the_lcsb


About the LCSB:
The Luxembourg Centre for Systems Biomedicine is Luxembourg’s flagship biomedical institution, dedicated to systems biology research. The multi-disciplinary team of 215 scientists split across 17 research groups work to uncover insights into complex biological / disease mechanisms which are applied to develop a comprehensive understanding of pathogenesis pathways, develop diagnostic tools as well as advise on potential therapies. Their research is applied to complex neurodegenerative disorders such as Parkinson’s disease, and used as an engine to identify new potential targets for therapy across various patient sub-populations.

For more information, visit https://wwwen.uni.lu/lcsb

Contact us

Get in touch to learn how we can add value to your business or career.